Literature DB >> 9787200

Rituxan in the treatment of cold agglutinin disease.

E J Lee, B Kueck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787200

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation.

Authors:  A Ship; W May; K Lucas
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

2.  Remission of cold hemagglutinin disease induced by rituximab therapy.

Authors:  T G Sparling; M Andricevic; H Wass
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

3.  Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.

Authors:  A Vassou; V Alymara; A Chaidos; K L Bourantas
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 4.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  [Rheumatoid arthritis and autoimmune hemolysis: B-cell depletion for remission induction in a patient with rheumatoid arthritis and cold agglutinin disease].

Authors:  P Lehmann; W Hartung; B Ehrenstein; J Schölmerich; M Fleck
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 6.  Rituximab in the treatment of autoimmune haemolytic anaemia.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Lallindra Gooneratne
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

7.  Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2011-04-10

8.  Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.

Authors:  Gideon Y Stein; Aliza Zeidman; Zinaida Fradin; Meir Varon; Amos Cohen; Moshe Mittelman
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

9.  B cells as a therapeutic target in autoimmune disease.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2003-03-19       Impact factor: 5.156

Review 10.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.